Rocket Pharmaceuticals (RCKT) Proxy filing summary

Executive summary

• The annual meeting will be held virtually on May 20, 2026, with voting on key proposals including director elections, auditor ratification, executive compensation, and a stock option exchange program.

• Proxy materials are distributed electronically to reduce costs and environmental impact, with paper copies available upon request.

• The company underwent a strategic reorganization in 2025, focusing on AAV cardiovascular gene therapy and reducing workforce and expenses.

• Financial highlights include FDA approval of KRESLADI™, lifting of a clinical hold on RP-A501, and a strengthened liquidity position supporting operations into 2027.

Voting matters and shareholder proposals

• Shareholders will vote on electing seven directors, ratifying EisnerAmper LLP as auditor, a non-binding say-on-pay vote, approval of a stock option exchange program, and any other business.

• The board recommends voting FOR all proposals.

• Shareholder proposals and nominations for the 2027 meeting must be submitted between January 20 and February 19, 2027.

Board of directors and corporate governance

• Seven director nominees are proposed, with two current directors not standing for re-election.

• The board is majority independent, with separate CEO and Chairman roles.

• Board committees include Audit, Compensation, and Nominating and Corporate Governance, all with independent members.

• Directors are encouraged to attend meetings and overboarding is monitored.